Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Overview
Explore Aardvark Therapeutics, Inc. Common Stock’s financial performance, market position, analyst ratings, and future outlook.
Aardvark Therapeutics, Inc. Common Stock (AARD)
Key Financials
Key Financials
Market Cap
31.8M
P/E Ratio
-0.47
EPS (TTM)
$-3.21
ROE
-0.72%
AARD Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Aardvark Therapeutics, Inc. Common Stock (NASDAQ: AARD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Aardvark Therapeutics, Inc. Common Stock's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of AARD on the NASDAQ shows an RSI of 20.21, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $7.98 for the NASDAQ listing.
Key metrics behind Aardvark Therapeutics, Inc. Common Stock's NASDAQ-traded stock include a P/E ratio of -0.47 and a market capitalization of 31.8M. Combined with our AI analysis, these give both institutional and retail investors a clear view of AARD on the NASDAQ.